Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Afluria Quad
- Development stage
- Approved
- Lead developer
- CSL Seqirus
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Afluria Quad is a quadrivalent inactivated influenza vaccine used for the prevention of influenza caused by the virus subtypes and types (A and B) contained in the vaccine. It contains purified hemagglutinin antigens from four different strains of influenza virus, selected annually based on recommendations to match circulating strains. The vaccine works by stimulating an immune response that leads to the production of antibodies against these viral antigens, providing protection against infection. It is administered as an intramuscular injection and is indicated for use in individuals 6 months of age and older (in some regions, only for those 5 years and older). Annual vaccination is recommended due to frequent changes in circulating influenza strains. The product is developed and manufactured by Seqirus.
- Brand names
- Afluria Quad
- Other names
- Afluria QuadrivalentAfluria Quadrivalent Southern Hemisphere
02
Targets
Influenza virus hemagglutinin receptor-binding domain
Beyond the preview
Go deeper on Afluria Quad.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Afluria Quad.